Everything you need to know about Emcure Pharmaceuticals IPO

Promo Code: WORLDCUP (65% Discount on Model Portfolios, Stock-O-Meter Plus & Fund-O-Meter Plus)
#EmcurePharmaceuticalsIPO #ipo2024 #stockmarketnews #investing #financialanalysis #IPOInvesting #EmcureIPO #stocks #marketanalysis #investmenttips #finance #EmcurePharma #investmentopportunity #marketnews #stockmarketinsights
In this video, we dive deep into everything you need to know about the Emcure Pharmaceuticals IPO. Discover key details such as the IPO date, price band, company background, financial performance, and market expectations. We analyze the potential risks and rewards for investors considering this IPO. Whether you're new to IPO investing or looking for insights into Emcure Pharmaceuticals, this video provides essential information to help you make informed decisions. Don't forget to like, comment, and subscribe for more updates on IPOs and stock market insights!
00:00 Start
02:29 IPO Details
04:16 Company Overview
06:01 Company Overview -Portfolio
09:55 Key Takeaway : Growth in recent years
10:21 Key Takeaway : Fast Growing Industry
10:45 Indian Pharma Market
11:27 Strong Anchor Book
13:11 Peer Comparison
15:28 Valuation
17:10 Peer Comparison (D/E)
17:39 Conclusion
Complete Fundamental Stock Analysis Tool - Stock-o-meter:
investyadnya.in/stock-o-meter
Research Based Ready-made Model Portfolios:
investyadnya.in/model-portfolios
Comprehensive Mutual Fund Reviews:
investyadnya.in/fund-o-meter
Yadnya Books and eBooks now available:
On Amazon - amzn.to/2XKtlks
On our website - investyadnya.in/books
Find us on Social Media and stay connected:
Whatsapp Channel - whatsapp.com/channel/0029Va6N...
Blog - blog.investyadnya.in
Telegram - t.me/InvestYadnya
Facebook Page - / investyadnya
Twitter - / investyadnya
#InvestYadnya #YIA
LEGAL DISCLAIMER:
Use of this information is at the user's own risk. The Company and its directors, associates and employees will not be liable for any loss or liability incurred to the user due to investments made or decisions taken based on the information provided herein. The investment discussed or views expressed herein may not be suitable for all investors. The users should rely on their own research and analysis and should consult their investment advisors to determine the merit, risks and suitability of recommendation. Past performance is not a guarantee for future performance or future results. Information herein is believed to be reliable, although its accuracy and completeness cannot be guaranteed. The images used may be copyright of the company or third party. As a condition to using the services, the user agrees to the terms of use of the website and the services.
DISCLOSURES UNDER SEBI (RESEARCH ANALYST) REGULATIONS, 2014:
Yadnya Academy Pvt. Ltd. (InvestYadnya) is registered with SEBI under SEBI (Research Analyst) Regulations, 2014 with registration no. INH000008349.
Disclosure with regard to ownership and material conflicts of interest
1. Neither Research Analyst nor the entity nor his associates or relatives have any financial interest in the subject Company;
2. Neither Research Analyst nor the entity nor its associates or relatives have actual / beneficial ownership of one per cent or more securities of the subject Company, at the end of the month immediately preceding the date of publication of the research report or date of public appearance;
3. Neither Research Analyst nor the entity nor its associates or his relatives have any other material conflict of interest at the time of publication of the research report or at the time of public appearance.
Disclosure with regard to receipt of Compensation
1. The Research Entity and its associates have not received compensation from the subject company in the past twelve months.
2. The subject company is not or was not a client during the twelve months preceding the date of recommendation.

[@mayurpatil427]

Big fan of gaurav sir, keep it up 👍
Took there finance planning session, was super helpful

[@gouthampai5055]

Thank you gaurav sir

[@pranaballavjena458]

Good analysis.

[@adityasah8231]

👍👌

[@jainjain4164]

Long term के लिए रखे या नहीं
50 शेयर खरीद ले बताये

[@shashikantbhardwaj9702]

Emcure is not a genuine brand in the generic market. I never chose.
Never know what market assessing

[@yashwantsahu6965]

jhantu company hai

[@ankutoonz]

koe lera he kya ipo emmcure ka

[@pradeepchethan3167]

Expensive valuation kindly check their receivables snd payables investors do t recommend for gmp Also, funny listing price not good to apply

[@CAPARTH89]

Aisa toh mama earth ke ipo mein bhi bola tha. Expensive hai blah blah. Fir bhi bumper opening mila tha usko.
So dont try to be fundamentally correct every time.

[@hrishi_t]

Uska koi lena dena nahi hota short term me listing gain mil jayega💯

[@yashveer5077]

Sab Pharma ka cutting ka game h

[@abhishekgb]

It's expensive. That's it

[@monojbauri3001]

Never subscribing to an IPO is bullshit

[@arnabroychoudhury8826]

it is not in top 10

[@srikanthgandhi6499]

Iam not Ecpetice in this type of business. So iam out

[@deepakkurdekar.7999]

I don't have expertise in this so I'm out.😂

[@mahesh84]

over expensive than existing players ,, why would i take this

[@rajathjain6672]

For listing gains?

[@yashwantsahu6965]

jhantu company hai

[@hrishi_t]

​@@yashwantsahu6965 you are biased 550 cr profit wale zhatu 😅